Oryzon Genomics Shares Final Findings from PORTICO Trial
Oryzon Genomics, S.A., a biopharmaceutical company in clinical stages that focuses on epigenetics, recently released the final findings from its Phase IIb PORTICO trial of vafidemstat, aimed at treating patients diagnosed with Borderline Personality Disorder (BPD). This crucial update was revealed during the European College of Neuropsychopharmacology (ECNP) Congress, highlighting significant progress in mental health treatments.
Notable Improvements in Trial Outcomes
The PORTICO trial highlighted impressive improvements across various clinical measures associated with BPD. Participants who received vafidemstat experienced marked reductions in agitation and aggression, as reflected in the State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger scale. Specifically, the trial found statistically significant results with a p-value of 0.0071, showing a noteworthy decline during Weeks 8–12.
Decrease in Overall Disease Severity
Moreover, the Borderline Evaluation of Severity Tool (BEST) showed promising improvements in the overall severity of the disease, with a p-value of 0.0260. This suggests that the treatment with vafidemstat could provide a more effective therapeutic strategy for managing BPD symptoms compared to data reported previously.
Effectiveness and Safety of Vafidemstat
Throughout the PORTICO trial, vafidemstat consistently demonstrated positive results across various efficacy endpoints. A T-Forest plot analysis revealed a significant treatment effect from vafidemstat over the placebo, emphasizing its potential as an innovative therapy for BPD. Additionally, the results from the Global Statistical Test (GST) confirmed a global treatment effect favoring vafidemstat, further reinforcing its therapeutic advantages in managing BPD.
Encouraging Feedback from the FDA
Recently, during an end-of-Phase II meeting, Oryzon presented these intriguing results to the FDA, discussing the prospects of moving forward with a registrational Phase III study for vafidemstat. The promising data not only suggest immediate plans for subsequent clinical trials, but they also place Oryzon in a favorable position as a leader in the development of an approved pharmacological treatment for BPD.
Reactions from Oryzon's Leadership
Dr. Michael Ropacki, Oryzon's Chief Medical Officer, expressed enthusiasm regarding the results, indicating that they reveal a hopeful new treatment pathway for those affected by BPD. The therapeutic mechanism, grounded in epigenetics, offers a compelling alternative without the usual side effects found in many current off-label medications. This could significantly enhance the quality of life for patients, positioning vafidemstat as a revolutionary option for managing BPD.
Oryzon's Commitment to Future Research
Oryzon remains deeply committed to advancing research into BPD and other central nervous system (CNS) disorders. The company is determined to explore and develop additional clinical trials, inspired by the robust evidence from the PORTICO study, to refine treatment options for patients. Oryzon's continued research and dedication to innovation in the epigenetics field place it in a significant position to enhance patient care.
Frequently Asked Questions
What is vafidemstat?
Vafidemstat is an oral, CNS-optimized LSD1 inhibitor designed to treat various CNS disorders, including BPD.
What were the key findings from the PORTICO trial?
The trial showed significant reductions in agitation and aggression among patients treated with vafidemstat compared to placebo.
How does vafidemstat work?
Vafidemstat works through an epigenetic mechanism, which helps manage symptoms without the common side effects of other treatments.
What is the future for vafidemstat?
Oryzon aims to prepare for a Phase III trial following positive FDA feedback based on PORTICO's results.
How significant are the results of the PORTICO trial?
The trial results are groundbreaking, marking the first time significant statistical outcomes have been achieved in a randomized Phase IIb trial for BPD.
